Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Eslami, Layli ^a   Merat, Shahin ^b   Malekzadeh, Reza ^b   Nasseri Moghaddam, Siavosh ^b   Aramin, Hermineh ^b  

^a GOLESTAN UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALL CAUSE MORTALITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER HISTOLOGY; MYALGIA; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; ENZYMOLOGY; FATTY LIVER; META ANALYSIS;

ALANINE TRANSAMINASE; FATTY LIVER; FENOFIBRATE; GAMMA-GLUTAMYLTRANSFERASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; SIMVASTATIN;

EID: 84897368255     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008623.pub2     Document Type: Review

References (62)

1. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al.Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Current Medical Research and Opinion 2006;22(5):873-83.
2. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomised placebo controlled trial. Journal of Clinical Gastroenterology 2009;43(10):990-4.
3. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidaemic patients. Atherosclerosis 2006;184:233-4.
4. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 2010;376:1916-22.
5. Carnelutti A, Donnini D, Nadalutti G, De Luca L, Cappello D, Cugini F, et al.Effect of statin therapy vs diet in hypercholesterolaemia patients affected by nonalcoholic steatohepatitis (NASH). Digestive and Liver Disease 2012;44S:S25.
6. Gomez-Dominguez E, Gisbert JP, Moreno- Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemic, non-alcoholic fatty liver patients. Alimentary Pharmacology and Therapeutics 2006;23:1643-7.
7. Han KH, Rha SW, Kang HJ, Bae JW, Choi BJ, Choi SY, et al.Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). Journal of Clinical Lipidology 2012;6(4):340-51.
8. Harlander JC, Kwo PY, Cummings OW. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120A:544.
9. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al.Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidaemia. Indian Journal of Gastroenterology 2004;23:131-4.
10. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al.Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Canadian Journal of Gastroenterology 2003;17(12):713-8.
11. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, et al.Efficacy and safety of high-dose pravastatin in hypercholesteraemic patients with well compensated chronic liver disease: results of a prospective, randomised, double blind, placebo-controlled, multicenter trial. Hepatology 2007;46(5):1453-63.
12. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193-6.
13. Tavakkoli H, Adilipour H, Ghaemaghami Z, Minakari M, Adibi P. Simvastatin in treatment of non-alcoholic steatohepatitis: a clinical trial. Govaresh 2009;14:28.
14. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.
15. Ahmed MH. Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scandinavian Journal of Gastroenterology 2006;41(5):631.
16. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065-74.
17. Bacon BR, Faravash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9.
18. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al.Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine 2003;163:553-64.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999;94:2467-74.
20. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Seminars in Liver Disease 2001;21(1):3-16.
21. Brunt EM. NASH: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8.
22. Brunt EM. Pathology of fatty liver disease. Modern Pathology 2007;20 Suppl 1:S40.
23. Cello JP, Grendell JH. The liver in systemic conditions. In: Zakim D, Boyer TD editor(s). Hepatology. Philadelphia: WB Saunders, 1990:1428.
24. Cheung O, Sanyal AJ. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008;28(4):351-9.
25. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009;50:772-80.
26. Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. In: Leuschner U, James OFW, Dancygier H editor(s). Steatohepatitis (NASH and ASH) - Falk Symposium 121. Lancaster: Kluwer Academic Publisher, 2001:322-42.
27. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46(4):734-42.
28. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 11. Art. No.: LIVER.
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
30. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al.Significant correlations between severe fatty liver and risk factors for metabolic syndrome. Journal of Gastroenterology and Hepatology 2007;22(12):2118-23.
31. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
32. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
33. Jakobsen JC, Gluud C. The necessity of randomized clinical trials. British Journal of Medicine and Medical Research 2013;3(4):1453-68.
34. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al.Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97.
35. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
36. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
37. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Human Pathology 1989;20:594-8.
38. Lomas J. Words without action? The production, dissemination, and impact of consensus recommendations. Annual Review of Public Health 1991;12:41-65.
39. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings 1980;55:434-8.
40. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
41. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
42. Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; Vol. 285:2486-97.
43. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Archives of Biochemistry and Biophysics 1996;325:242-8.
44. Poonam M, Zobair M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). American Journal of Gastroenterology 2007;102:2716-7.
45. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell W. The natural history of nonalcoholic steatohepatitis: a follow up study of forty-two patients for up to 21 years. Hepatology 1990;11(1):74-80.
46. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al.A lipidemic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46(4):1081-90.
47. Rofsky NM, Fleshaker H. CT and MRI of diffuse liver disease. Seminars in Ultrasound, CT, and MR 1995;16:16-33.
48. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
49. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al.The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
50. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al.Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120(5):1183-92.
51. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
52. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
53. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
54. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. Journal of Hepatology 2009;51(3):433-5.
55. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al.Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD004816.pub5]
56. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. American Journal of Cardiology 1988;62:28J.
57. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, et al.Statins for acute coronary syndrome. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD006870.pub2]
58. Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, et al. Specific role for acyl CoA: Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 2009;50:434-42.
59. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006;147(2):943-51.
60. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. American Journal of Physiology, Endocrinology and Metabolism 2006;291(2):E275-81.
61. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
62. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. American Journal of Clinical Pathology 2007;128:837-4.